Cholesterol-dependent cytolysins impair pro-inflammatory macrophage responses

Pushpak Bhattacharjee1,2 & Peter A. Keyel1

Necrotizing soft tissue infections are lethal polymicrobial infections. Two key microbes that cause necrotizing soft tissue infections are Streptococcus pyogenes and Clostridium perfringens. These pathogens evade innate immunity using multiple virulence factors, including cholesterol-dependent cytolysins (CDCs). CDCs are resisted by mammalian cells through the sequestration and shedding of pores during intrinsic membrane repair. One hypothesis is that vesicle shedding promotes immune evasion by concomitantly eliminating key signaling proteins present in cholesterol-rich microdomains. To test this hypothesis, murine macrophages were challenged with sublytic CDC doses. CDCs suppressed LPS or IFN-γ-stimulated TNFα production and CD69 and CD86 surface expression. This suppression was cell intrinsic. Two membrane repair pathways, patch repair and intrinsic repair, might mediate TNFα suppression. However, patch repair did not correlate with TNFα suppression. Intrinsic repair partially contributed to macrophage dysfunction because TLR4 and the IFN-γR were partially shed following CDC challenge. Intrinsic repair was not sufficient for suppression, because pore formation was also required. These findings suggest that even when CDCs fail to kill cells, they may impair innate immune signaling responses dependent on cholesterol-rich microdomains. This is one potential mechanism to explain the lethality of *S. pyogenes* and *C. perfringens* during necrotizing soft tissue infections.

1Department of Biological Sciences, Texas Tech University, Lubbock, TX, 79409, USA. 2Present address: Department of Cell Biology and Biochemistry, Texas Tech University Health Science Center, Lubbock, TX, 79430, USA.

Correspondence and requests for materials should be addressed to P.A.K. (email: peter.keyel@ttu.edu)
The host's innate immune response is critical to promoting survival during NSTI because the disease spreads rapidly. S. pyogenes is controlled by macrophages, which eliminate bacteria and secrete pro-inflammatory cytokines, including Tumor Necrosis Factor α (TNFα). TNFα production is induced by a wide variety of signaling pathways, including pro-inflammatory cytokines like TNFα itself and Interferon γ (IFNγ), and pattern-recognition receptors such as Toll-like receptors (TLRs). Following TLR activation, the adaptor proteins MyD88 and/or Trif are recruited to the TLR, where they mediate downstream TLR signaling. TLR signaling induces pro-inflammatory cytokine expression and increases cell surface expression of both activation markers like CD69, and costimulatory proteins like CD80, CD83 and CD86. Ligation of TLRs also induces the priming of the inflammasome. The inflammasome is a multiprotein complex that senses a wide variety of danger signals. It is comprised of a sensory Nod-like Receptor (NLR), the adaptor Pycard, and an inflammatory Caspase (Casp)38,39. The best studied inflammasome, the NLRP3 inflammasome, senses membrane damage, like that caused by CDCs. Following activation of the sensory NLR, NLRP3, Casp1 is activated, leading to pro-inflammatory IL-1β and IL-18 secretion and the programmed cell death pathway termed pyroptosis. Pyroptosis is the inflammatory lysis of cells by Casp1 or Casp11 mediated cleavage of Gasdermin D. This lysis prevents bacteria from sheltering within the macrophages and promotes recruitment of neutrophils and other innate effectors to kill the bacteria. Thus, innate immune cells detect and control pathogens through multiple inflammatory approaches.

Along with inflammatory responses, immune cells must also survive long enough to respond to pathogens. All nucleated eukaryotic cells prevent lysis and plasma membrane disruption through membrane repair. Membrane repair is a poorly understood set of Ca2+ dependent processes that restore membrane integrity. Following membrane disruption by a CDC like SLO, the cell activates at least two pathways, patch repair and intrinsic repair. Patch repair is the hetero/homotypic fusion of internal vesicles with the plasma membrane, which patches the damaged site. Intrinsic repair is the sequestration and shedding of toxins on microvesicles. While these repair mechanisms help the cell by restoring membrane homeostasis, it is not clear if pathogens can exploit this repair process to promote immune evasion. Many immune activation receptors, including TLR4 and the IFNγ receptor (IFNγ-R), localize to cholesterol-rich microdomains. PFO also localizes to cholesterol-rich microdomains, so it is possible that intrinsic repair could remove immune receptors along with CDCs during repair. Several proteins are shed following CDC challenge, including the IL-6 receptor, and GPI-anchored proteins like CD14, alkaline phosphatase, and murine cytomegalovirus protein m157. The functional consequences of shedding during intrinsic repair are unclear. It is possible that pathogens hijack membrane repair to block immune cell activation.

Here we tested the hypothesis that bacterial CDCs hijack membrane repair to suppress immune cell function. We found that the CDCs SLO and PFO temporarily impair macrophage responses to LPS and pro-inflammatory cytokines like IFNγ, as measured by TNFα production and surface expression of activation markers CD69 and CD86, without causing significant cell death. We found that TLR4 and IFNγ-R1 were both shed on microvesicles during intrinsic repair. In contrast, patch repair did not correlate with TNFα inhibition. Mutant toxins that enhanced membrane repair more potently inhibited macrophage responses. Overall, these findings suggest one mechanism for the immune evasion caused by C. perfringens and S. pyogenes during NSTI.

Results

CDCs functionally impair macrophages. During a polymicrobial NSTI infection, both Gram positive and negative organisms could be present. To examine how CDCs could interact with other pathogen-associated molecular patterns that could be present during infection, we challenged murine C57BL/6 (B6) bone-marrow derived macrophages (BMDM) sequentially first with a CDC and then with a TLR ligand like LPS. We first determined the extent of TNFα production by BMDM to varying doses of LPS and the CDC SLO. BMDM were first challenged with three sublytic doses of SLO (250, 500, 1000 HU/mL), and then stimulated with varying doses of LPS for 2 h. We measured TNFα production by intracellular cytokine staining of live cells. We found that unstimulated and 10 EU/mL LPS did not induce TNFα production, but ~60% to 75% of BMDM produced TNFα when stimulated with 100 or 1000 EU/mL LPS (Fig. 1A). We found that 250 HU/mL SLO did not significantly alter TNFα production in BMDM treated with any dose of LPS, but 500 and 1000 HU/mL SLO caused a significant decrease in the proportion of TNFα positive live cells following 100 or 1000 EU/mL LPS stimulation (Fig. 1A). BMDM challenged with the pore deficient “monomer-locked” SLO (SLO ML) did not reduce TNFα production, indicating that this effect was not due to impurities in the toxin preparation and required oligomerization and/or pore formation of SLO (Fig. 1A). We next confirmed that SLO treatment was sublytic by measuring the proportion of dead cells in each population. Typically, cell death was <10%, except at the highest doses of LPS and SLO, which led to ~20% death (Fig. 1B). Based on this titration, we chose to perform future experiments with sublytic 500 HU/mL SLO followed by 100 EU/mL LPS exposure. Overall, these data suggest that SLO pretreatment may block TNFα production by BMDM.

We next determined the breadth of this functional impairment. We used a second CDC, PFO, because it is also involved in NSTI and immune evasion. We further tested additional TLR ligands and cytokines that induce TNFα production in BMDM. We challenged BMDM with or without SLO ML, SLO WT or PFO for 10 min and then stimulated them without or with the TLDR agonist LPS, TLDR agonist polynosinic-polycytidylic acid (poly I:C), TLDR1/2 agonist Pam3CSK4, or IFNγ for 2 h and evaluated intracellular TNFα in live cells. We found that in response to LPS or IFNγ, PFO and SLO both similarly inhibited TNFα production (Fig. 1C). PFO, but not SLO, impaired TNFα production induced by TLDR3 (Fig. 1C). Neither CDC blocked TNFα production induced by TLDR2 (Fig. 1C). We measured necrosis in these cells and found that PFO and SLO were sublytic under most toxin/TLR ligand combinations. The greatest cytotoxicity was observed in BMDM treated with both CDCs and a TLDR2 ligand (Fig. 1D). Importantly, TNFα production in these cells was not impaired, despite the increased cell death, indicating that cell death does not account for the attenuation of TNFα production. We next tested the...
Figure 1. SLO impairs macrophage function. (A,B) BMDM were unchallenged (control) or challenged with 250 HU/mL, 500 HU/mL, 1000 HU/mL SLO WT or a mass of monomer-locked SLO (SLO ML) equivalent to the highest SLO WT dose for 10 min at 37 °C. Toxin was neutralized with serum. Cells were primed with the indicated concentrations of LPS for 2 h. BFA was added 30 min after LPS challenge. Cells were harvested, stained with Ghost Red 780, fixed, permeabilized, stained for intracellular TNFα and analyzed by flow cytometry. The percentage of TNFα positive cells gated on live cells (A) or the percentage of dead cells (B) is shown. (C,D) BMDM were unchallenged (control) or challenged with 500 HU/mL SLO WT, PFO or an equivalent mass amount of SLO ML for 10 min at 37 °C. Toxin was neutralized with serum. Cells were stimulated with no ligand, 100 EU/mL LPS, 10 μg/mL poly I:C (PIC), 1 μg/mL Pam3CSK4 (PAM), or 75 ng/mL IFNγ for 2 h. BFA was added 30 min after ligand challenge. Cells were harvested, stained and analyzed as in (A). The percentage of TNFα positive cells gated on live cells (C) or the percentage of dead cells (D) is shown. (E) BMDM were treated as in (C), except they were all stimulated with 100 EU/mL LPS for the indicated time points. BFA was added...
time frame over which TNFα production was reduced. We challenged BMDM with CDCs, then exposed them to LPS for 0–6 h and measured TNFα production (Fig. 1E). We found that TNFα production was most potently inhibited at 2 h, but returned to normal levels 4 h after SLO challenge but was not fully restored following PFO challenge (Fig. 1E). Overall, these data show that CDCs from *S. pyogenes* and *C. perfringens* selectively and transiently inhibit TNFα production induced by LPS or IFNγ.

We next tested the extent of impairment in macrophages by examining surface expression of other activation markers and costimulatory proteins, like CD69, CD86 and CD80, following TLR stimulation. We found that LPS and poly I:C, but not Pam3SCK4, increased CD69, CD86 and CD80 surface expression (Fig. 1F–H), consistent with the Trif-dependent activation of costimulatory proteins<sup>37</sup>. Pretreatment with either SLO WT or PFO, but not SLO ML, reduced CD69 surface expression (Fig. 1F). PFO, but not SLO WT, significantly decreased CD86 surface levels (Fig. 1G). Interestingly, CD80 levels were not affected by either CDC (Fig. 1H). This suggests that PFO specifically targets immune activation because CD80 is associated with immune tolerance<sup>55,56</sup>. Overall, CDCs induced dysfunction of multiple innate immune mechanisms.

**Functional impairment of macrophages is not due to cell death.** Although we limited our examination to cells with intact plasma membranes (eg Ghost Red impermeant), it is possible that the functional impairment we observed could be due to an alternative form of cell death or due to paracrine effects of Danger-Associated Molecular Patterns (DAMPs) released by the small subset of dying cells. We first examined alternative forms of cell death. We tested whether pyroptosis played any role in macrophage dysfunction by comparing the ability of CDCs to impair unprimed WT BMDM or pyroptosis-deficient Casp1/11<sup>−/−</sup> BMDM. We found no difference in the ability of SLO WT or PFO to block TNFα production between WT BMDM and Casp1/11<sup>−/−</sup> BMDM (Fig. 2A). The limited cell death we observed following CDC treatment was not due to pyroptosis, since both populations had a similar, low (<15%) extent of cell death (Fig. 2B). We next tested apoptosis, because other groups reported that SLO can induce apoptosis<sup>22,24</sup>. We measured the percentage of apoptotic cells by staining cells with Annexin V and propidium iodide (PI) after challenge with nothing, SLO ML, SLO WT, or PFO followed by LPS stimulation for 4 h or 24 h. PFO, but not SLO, caused a minor, but statistically significant, increase in apoptosis at 4 h following LPS stimulation (Fig. 2C). After 24 h, about 40% of PFO challenged cells were Annexin V<sup>−</sup>/PI<sup>−</sup>, whereas SLO WT still did not show any significant apoptosis (Fig. 2C). At 24 h, cell death due to necrosis was also elevated in cells pretreated with SLO WT or PFO (Fig. 2C). These data indicate that SLO does not impair macrophages through pyroptosis or apoptosis.

We next tested the possibility that macrophage impairment is mediated by DAMPs released by the small population of dead cells present following toxin challenge. To rule out interference from dead cells, we sorted living cells after SLO WT challenge but prior to LPS stimulation. We found that SLO WT impaired TNFα production even in the absence of dead cells (Fig. 2D). We confirmed that less than 5% of cell death occurred in the sorted cell population after 2 h of LPS stimulation (Fig. 2E). Overall, these data indicate that CDCs impair macrophages independently of cytotoxicity.

**Macrophages are impaired prior to TNFα mRNA synthesis.** Since macrophage dysfunction was not a consequence of cytotoxicity, we next determined the stage at which TNFα production is attenuated by CDCs. CDCs are pore-forming toxins, so it is possible that either TNFα protein or mRNA leaks out of the pores. Leakage of mRNA or protein from the cell can be tested by measuring both relative TNFα production and total RNA yield. If we measure a decrease in total RNA yield, it would indicate that mRNA leaked from the cell. If we measure no change in RNA yields or relative mRNA levels, it would indicate that TNFα production is blocked downstream of mRNA production. Finally, if we measure a specific decrease in TNFα mRNA, it would indicate that impairment occurs prior to TNFα mRNA synthesis and is not a result of mRNA or TNFα protein leakage from the cell. We challenged BMDM with nothing, SLO ML, SLO WT or PFO, then stimulated them with LPS for 2 h or 4 h and then measured their TNFα and β-actin mRNA expression by real-time PCR. We had normal RNA yields for all conditions. We observed a 50-fold increase in TNFα mRNA following 2 h of LPS stimulation and challenge with no toxin or SLO ML (Fig. 3A). In contrast, TNFα mRNA did not show a comparable relative increase in BMDM challenged with either SLO WT or PFO (Fig. 3A). Consistent with the temporary nature of the impairment, after 4 h of LPS stimulation, we observed no difference in relative mRNA levels between cells challenged and unchallenged with CDCs (Fig. 3A). To rule out the possibility that cell death accounts for the changes we observed in TNFα mRNA, we simultaneously measured cell death by PI staining a subsample of each group of cells. We found no significant amount of cell death due to CDC challenge and LPS stimulation under these conditions (Fig. 3B). These data suggest that the observed impairment is not due to leakage of TNFα mRNA or protein from the cell, but instead occurs prior to TNFα mRNA synthesis.

**Patch repair does not account for macrophage dysfunction.** Since impairment occurs prior to mRNA synthesis and is not due to TNFα leakage through toxin pores, it is possible that the functional impairment of macrophages is caused by processes that seal off and remove toxin pores—membrane repair. Two membrane repair mechanisms are used by cells to reseal lesions from CDCs: intrinsic repair and patch repair<sup>16</sup>. Intrinsic repair is the lipid-mediated sequestration and shedding of CDCs<sup>16</sup>, while patch repair is the Ca<sup>2+</sup>-dependent
Figure 2. Functional impairment of macrophages by SLO is not due to cell death. (A, B) B6 (WT) or Casp1/11−/− BMDM were treated as in Fig. 1C using 100 EU/mL LPS. The percentage of TNFα positive live cells (A) or percentage of dead cells (B) is shown. (C) BMDM were unchallenged or challenged with 500 HU/mL SLO WT, PFO or equivalent mass of SLO ML for 10 min, stimulated with 100 EU/mL LPS for 4 h or 24 h, harvested, stained with Annexin V and PI and analyzed by flow cytometry. The percentage of apoptotic (Annexin V+/PI−) or dead (PI+) cells is shown. (D-E) BMDM unchallenged or challenged with 500 HU/mL SLO for 10 min at 37 °C were sorted using a BD FACS Aria III to collect living cells. Sorted cells were stimulated with LPS and stained for TNFα as described in Fig. 1C. The percentage of TNFα positive cells gated on live cells (D) or the percentage of dead cells in this sorted population (E) is shown. Graphs represent mean ± sem of three independent experiments. **p < 0.01, *p < 0.05.
hetero- and homotypic fusion of internal vesicles and proteins that seal off the damage.\(^45,46\) We first tested if patch repair drives impairment. We measured patch repair using two methods: entry of the membrane impermeant, fixable dye FM1–43X into the cell\(^57\) and surface staining of Lamp1 (CD107) to measure lysosomal fusion with the plasma membrane.\(^58\) FM1–43X fluoresces only when bound to lipids. Increased FM1–43X fluorescence reflects an increased labeling of internal membranes. Brighter cells are those that took longer to reseal, demonstrating reduced patch repair capacity. If the extent of patch repair correlates with impairment, we predict FM1–43X\(_{\text{low}}\) cells would show a greater degree of TNF\(_{\alpha}\) inhibition. We challenged BMDM with nothing, SLO ML, SLO WT, or PFO for 10 min at 37 °C in presence of FM1–43X, washed, stimulated them with 2 h LPS and measured the proportion of TNF\(_{\alpha}\) positive live cells in FM1–43X\(_{\text{high}}\) and FM1–43X\(_{\text{low}}\) subsets. We found no difference in the proportion of TNF\(_{\alpha}\) positive live cells when we gated on either the FM1–43X\(_{\text{high}}\) or FM1–43X\(_{\text{low}}\) populations under any condition (Fig. 4A). This suggests that impairment does not correlate with patch repair in BMDM.

To confirm these results, we used a second approach to assess patch repair. During patch repair, internal membranes, including lysosomes, fuse with the plasma membrane.\(^58,59\) As with the fusion of Natural Killer cell secretory granules,\(^60,61\) this process elevates the levels of Lamp1 on the cell surface.\(^58\) Cells undergoing extensive patch repair should show higher surface Lamp1 levels than other cells in the population. We measured surface Lamp1 expression on cells following CDC challenge and LPS stimulation. When we gated on Lamp1\(_{\text{high}}\) and Lamp1\(_{\text{low}}\) populations, we found SLO WT and PFO equally reduced TNF\(_{\alpha}\) production in both populations (Fig. 4B).

Together, these data indicate that macrophage functional impairment does not correlate with patch repair.

**Activation receptors are shed following CDC challenge.** Since patch repair did not correlate with macrophage impairment, we next tested if macrophage impairment is caused by intrinsic repair. Intrinsic repair is the sequestration and shedding of toxin molecules from the plasma membrane, so activation receptors could also be shed from the membrane during intrinsic repair. To test the hypothesis that key activation receptors are shed from BMDM along with active CDCs during intrinsic repair, we challenged BMDM with nothing, SLO ML, SLO WT, or PFO and then we isolated microvesicles (MV) from the cells. Consistent with previous results,\(^46,52,54,62\) we found that SLO WT and PFO are shed on MV, whereas SLO ML, which does not trigger intrinsic repair, did not localize to MV (Fig. 5A, Supplementary Fig. S1). We measured activation receptors present in the MV fraction,
and found that IFN-γR1 was shed following SLO or PFO challenge, while TLR4 was shed following SLO challenge (Fig. 5A, Supplementary Fig. S1). In contrast to previous results 53, we did not observe shedding of CD14 (Fig. 5A, Supplementary Fig. S1). We next examined the TLR4 signaling adaptors MyD88 and Trif. We found that SLO WT and PFO induced shedding of MyD88, but not Trif (Fig. 5A, Supplementary Fig. S1). To control for contamination of MV by cell debris, we verified that the plasma membrane associated, GPI-anchored protein Alkaline Phosphatase was shed in MV, while the nuclear envelope proteins Lamin A/C were not shed (Fig. 5A, Supplementary Fig. S1). We further determined the cholesterol to phospholipid ratio of MV. The high speed MV pellet from control cells had a cholesterol to phospholipid ratio of 0.092 ± 0.047 (mean ± sem), while the ratio for MV shed from SLO- or PFO-challenged cells was 0.296 ± 0.049 and 0.363 ± 0.040, respectively (p = 0.0398 and 0.012 vs control by ANOVA). Values for MV from SLO- or PFO-challenged BMDM are consistent with previous measurements of the cholesterol to phospholipid ratio for the plasma membrane63,64. Also consistent with previous results 16, β-Actin was present in all three fractions following treatment with cytotoxic CDCs (Fig. 5A, Supplementary Fig. S1). These data suggest that CDCs trigger shedding of activation receptors during intrinsic repair.

We next tested if we could change the extent of activation receptor shedding by controlling the extent of intrinsic repair. In order to control the extent of intrinsic repair, we used the well-characterized SLO mutants SLO N402E (array-locked SLO) and N402C (SLO N402C)15,16,18. Array-locked SLO triggers reduced intrinsic repair compared to SLO WT, while the mixture of pores and linear oligomers formed by SLO N402C triggers increased intrinsic repair at equivalent hemolytic doses15,16. We challenged BMDM with SLO ML, SLO WT, an equivalent hemolytic dose of SLO N402C, or an equivalent mass of array-locked SLO to SLO N402C and isolated MV. As expected, we found that SLO N402C was more extensively shed than SLO WT, while array-locked SLO was not as extensively shed, and SLO ML was minimally shed (Fig. 5B, Supplementary Fig. S2). We measured the shedding of the TLR4 pathway under these conditions, and found that TLR4 and MyD88 were more extensively shed compared to SLO WT (Fig. 5B, Supplementary Fig. S2).
shed following SLO N402C challenge, and less so with array-locked SLO (Fig. 5B, Supplementary Fig. S2). Trif was not shed under any condition (Fig. 5B, Supplementary Fig. S2). Alkaline Phosphatase shedding was similar to TLR4 and MyD88, confirming that SLO N402C induced more shedding, while array-locked SLO induced less shedding than SLO WT (Fig. 6B). Lamin A/C was found strictly in the cell lysate, indicating cellular integrity in all samples (Fig. 5B, Supplementary Fig. S2). Overall, these findings suggest that TLR4 and MyD88 are shed by intrinsic repair.

Functional impairment requires pore formation. We next tested the relative contribution of receptor shedding to macrophage impairment. We compared the extent of TNFα production following SLO challenge with our various toxin mutants and LPS stimulation. Since SLO N402C is 10-fold less hemolytic than SLO WT15, we used both an equivalent mass of SLO N402C or an equivalent hemolytic dose of SLO N402C (N402C*) to SLO WT. We found that both SLO WT and an equivalent mass of SLO N402C reduced the proportion of TNFα positive cells at 2h, but not at 4h (Fig. 6A). However, an equivalent hemolytic dose of SLO N402C impaired TNFα production at both 2 and 4h (Fig. 6A). Heat inactivation of SLO N402C completely reversed this effect, indicating that functional SLO N402C was needed (Fig. 6A). However, intrinsic repair alone may not be sufficient for this phenotype, since an equivalent mass of array-locked SLO to SLO N402C did not impair TNFα production to the same degree in LPS stimulated BMDM (Fig. 6A). We next tested the ability of these mutant toxins to block CD69 expression (Fig. 6B). Similar to SLO WT, SLO N402C* reduced CD69 expression in BMDM (Fig. 6B). In contrast,
Discussion

In this study, we describe the ability of CDCs to suppress immune cells by blocking pro-inflammatory macrophage responses. This blockade appears to be cell intrinsic and mediated by the membrane repair response
to CDCs, specifically by the shedding of activation receptors during intrinsic repair. We propose a model of host-pathogen interactions starting with an attempt by pathogenic bacteria to kill cells using pore-forming toxins. Cells resist toxin lethality via membrane repair. Bacteria then hijack membrane repair to force elimination of surface immune activation receptors like TLR4 and IFN-γ. Immune cells respond with intracellular activation receptors like NLRP3 to secrete DAMPs and cytokines like IL-1β. Bacteria in turn encode separate proteins to block DAMPs and cytokines. Together, these results provide mechanistic insight into CDC-mediated immune evasion mechanisms. These immune evasion mechanisms may contribute to the pathogenicity and mortality of NSTI.

We found that CDCs promote the shedding of activation receptors on microvesicles. This extends the previous study showing that the IL-6 receptor and GPI-anchored proteins are shed by SLO 16,52–54. Although a previous study observed the shedding of the GPI-anchored CD14 53, to our surprise, we did not observe CD14 shedding. It is possible that this difference is due to assay conditions or to the use of murine vs human macrophages. Regardless, our results link immune receptor shedding to intrinsic membrane repair. We found that intrinsic repair was more important for the immune suppression phenotype than patch repair. This is consistent with our mechanism of receptor elimination by the shedding that occurs during intrinsic repair, and not by the hetero/ homotypic fusion of vesicles that occurs during patch repair. However, our finding that pore competence was necessary for the functional impairment of macrophages suggests that patch repair or other internal events may still enhance immune suppression. Future work can address the mechanism by which pore competence induces immune suppression.

We conclude from our data that immune suppression required pore formation. However, we cannot rule out the possibility that there is a threshold requirement for activation receptors. It is possible that array-lock SLO, which also promotes intrinsic repair 48–50, does trigger the same degree of immune suppression. However, we think this is unlikely based on our western blots showing a similar extent of TLR4 shedding. Interestingly, we never observed complete removal of either TLR4 or IFN-γ. It is possible that the remaining cell-associated receptors are not capable of signaling, or that a certain receptor density is required for productive signaling. It is also possible that in addition to receptor shedding, CDCs disrupt the ability of these receptors to signal. Both CDCs we examined, SLO and PFO, form 50–70 subunit pores 14. Each subunit can theoretically engage cholesterol and CDCs localize to cholesterol-rich microdomains 51,65,66. This has the potential to disrupt cholesterol-rich microdomain organization, especially when multiple toxin pores are sequestered in a relatively limited space. Disruption of cholesterol-rich microdomains can abrogate both TLR4 and IFN-γ signaling 48–50. It is possible that in addition to shedding, CDCs further disrupt signaling by altering cholesterol-rich microdomain organization. Interestingly, TLR4 localization to cholesterol-rich microdomains is enhanced by MyD88 dependent TLR4 signaling 67. Under these circumstances, we predict this would increase the amount of TLR4 shed and/or present in the disrupted area. Indeed, a previous report suggests that membrane repair interferes with B cell receptor signaling 68, though they did not examine the contribution of B cell receptor shedding to their phenotype. Future work will aim to dissect the contribution of cholesterol-rich microdomain remodeling and microvesicle shedding to the regulation of cell signaling and membrane repair.

Membrane repair is fundamentally a cell protective response. During CDC attack, membrane repair is critical for maintaining cell viability 48–50. In some cases, membrane repair further promotes immune responses 15,68. For example, we have previously shown that mutant toxins which provoke increased repair responses and reduced lethality (e.g. SLO N402C) lead to increased IL-1β secretion 15. In this circumstance, membrane repair preserves the cell long enough for it to execute a pro-inflammatory pyroptotic program 15. Similarly, during necroptosis, membrane repair prolongs cell survival from the pore-forming toxin Mixed Lineage Kinase-Like long enough to promote chemokine secretion and cross-presentation to T cells 69. Overall, membrane repair is generally beneficial to the host.

However, membrane repair can also be subverted by pathogens to attenuate the immune response. Previously, immune evasion has been attributed to CDCs, including both SLO 21,22,29 and PFO 4–8,23. Both CDCs are critical for pathogen virulence in vivo 5,9,23. Although other groups have suggested that necrosis or apoptosis 21,22 may underlie immune evasion, we show here that macrophages, like neutrophils 29, can be inactivated without their death. We suggest that the mechanism of immune suppression occurs at least partially through the shedding of activation receptors on microvesicles. We show that TLR4 and IFN-γ are shed, while previous work has suggested IL-6 receptor and CD14 are shed 53. Although TNFα production is only transiently (2–4 h) impaired, we observed long-term effects on CD69 and CD86 surface expression. The selective blockade of CD86 instead of CD80 suggests that pathogens like C. perfringens could potentially further promote immunosuppression by altering the relative surface expression of CD86 and CD80 on antigen-presenting cells. Taken all together, these immune evasion strategies could account for the accumulation of immune cells that do not enter necrotic tissue during gas gangrene 17. In contrast, during necrotizing fasciitis, macrophages infiltrate the infected area, but are inactivated and thus unsuccessful in clearing the bacteria 59–61. Overall, CDCs hijack membrane repair to promote immune evasion.

In response to these immune evasion strategies, we note that immune cells can sense and respond to CDCs with alternative pro-inflammatory mechanisms. The cytoplasmic sensor NLRP3 detects membrane disruption induced by CDCs, leading to Casp1 and inflammasome activation. As a result, CDC pore-formation potently induces IL-1β 15,40,41. However, bacteria have evolved separate mechanisms to counter this pro-inflammatory response. In the case of S. pyogenes, SLO is closely associated with a second virulence factor, NAD+–glycohydrolase (Spn) 10–13. Spn significantly enhances SLO-mediated cytotoxicity, but it also inactivates IL-1β 13. Inactivation of IL-1β allows S. pyogenes to evade this immune response. This illustrates how membrane repair fits into the wider context of host-pathogen interactions.

These host-pathogen interactions may be more specific for rapid NSTIs. Previous studies claimed that CDCs from S. pneumoniae and Bacillus anthracis activate TLR4 and promote apoptosis 70–72, which is the opposite of
what we find here. One explanation for the discrepancy in results is that we used different toxins and different time points. We examined earlier time points likely to be more relevant during NSTI. Typically, other studies examined TNFα mRNA at least 4 h after pneumonia (S. pneumoniae) or anthrolysin O (Bacillus anthracis) challenge, which is more relevant for the diseases caused by those pathogens. If CDCs bind to TLR4, it is possible that they act as weaker agonists and/or block LPS-dependent TLR4 activation, requiring longer times to promote activation. Alternatively, immune cells might enhance TNFα production at later time points in an attempt to compensate for earlier inhibition. Future studies could examine the temporal response of TNFα to different bacterial CDCs to determine the relative contributions of binding, timing and toxin structure to this discrepancy. Regardless, all of these studies serve to underscore the importance of TNFα production during pathogen control, and delineate steps both host and pathogen use to control TNFα production.

Overall, we propose that bacteria hijack the shedding that occurs during intrinsic membrane repair. This becomes an immune evasion mechanism by which TNFα production and the surface expression of activation markers and costimulatory receptors are blocked. This mechanism may account for the pathophysiologically and mortality caused by C. perfringens and S. pyogenes. Although our system models cooperative polymicrobial immune evasion by using LPS (Gram negative pathogens) and a CDC (Gram positive pathogens) that occurs during some NSTIs, it is possible that these pathogens also target TNFα induction by proinflammatory cytokines during single microbe infections. Both C. perfringens and S. pyogenes also causes septic shock, and septic cardiomyopathy. This suggests that intrinsic membrane repair may serve as one key host-pathogen interface in a broad range of diseases.

Materials and Methods

Reagents. All reagents were from Thermofisher Scientific (Waltham, MA) unless otherwise noted. The pBAD-GII plasmid encoding His-tagged SLO was a kind gift from Michael Caparon (Washington University in St Louis, St Louis, MO). Cysteine-less His-tagged PFO in PET22 was a generous gift from Rodney Tweten (University of Oklahoma Health Sciences Center, Oklahoma City, OK). Cysteine-less (C530A) SLO, monomer-locked (G398V/G399V) SLO, array-locked (N402E) and N402C SLO were previously described. Anti-Lamin A/C was obtained from the Developmental Studies Hybridoma Bank, created by the NICHD of the NIH and maintained at The University of Iowa, Department of Biology, Iowa City, IA 52242. Anti-Lamin A/C (MANLAC-A7-s) was deposited to the DSHB by G.E. Morris (DSHB Hybridoma Product MANLAC1(4A7)). Anti-Alkaline Phosphatase EPR4477 rabbit monoclonal antibody (rAb) (Catalog: GTX62596) and anti-β-actin AC-15 mouse monoclonal antibody (mAb) (Catalog: GTX26276) were obtained from GeneTex (Irvine, CA). Anti-IFN-α1-gi polyclonal antibody (Catalog: 1026-GR) was from R&D Systems (Minneapolis, MN). Anti-Streptolysin O 6D11 mAb (Catalog: NB1-05126), anti-CD14 4B4F12 mAb (Catalog: NB2-37291), and anti-TLR4 76B357.1 rAb (NB100–56566SS) were from Novus Biologicals (Littleton, CO). Anti-MyD88 O91B8 mAb (Catalog: 675802), anti-TR1 H4B01 mAb (Catalog: 657102), FITC-conjugated anti-CD69 H1.2F3 (Catalog: 104506), PE-conjugated anti-CD80 16–10A1 (Catalog: 104708), APC-conjugated anti-CD86 GL-1 (Catalog: 105012), FITC-conjugated anti-TNFα MP6-xT22 (Catalog: 506304), FITC-conjugated anti-Lamp1 1D4B (Catalog: 121608) antibodies and Brefeldin A were from BioLegend (San Diego, CA). HRP-conjugated antiamouse (Catalog: 711–035–151), anti-rabbit (Catalog: 711–035–152) and anti-Goat (Catalog: 705–035–147) antibodies were from Jackson ImmunoResearch (West Grove, PA). Ghost Red-780 was from Tombo Biosciences (San Diego, CA). Ultrapure LPS, poly I:C and Pam3CSK4 were from Invivogen (San Diego, CA). IFNγ recombinant protein was from ebiosciences (San Diego, CA).

Recombinant Toxins. Toxins were purified as previously described. Briefly, log-phase E. coli BL21 were induced with 0.2% arabinose (SLO), or 0.2 mM IPTG (PFO) for 3 h at room temperature and purified using Nickel-NTA beads. Protein concentration was determined by Bradford Assay and hemolytic activity was determined as previously described. Specific activity for toxins was 4.5 × 10^10–1.28 × 10^10 HU/mg for SLO WT, 8.82 × 10^10 HU/mg for PFO, 4.8 × 10^10 HU/mg for SLO N402C. Pore-deficient toxins SLO G398V/G399V (SLO monomer-locked), and SLO N402E (SLO array-locked) had a specific activity of <10 HU/mg. The sublytic dose of toxin used was the highest concentration of toxin that killed <20% of target cells. For BMDM, this was 500 HU/mL, consistent with our previous results.

Mice. All mice were housed and maintained at Texas Tech University, adhering to the Guide for the Care and Use of Laboratory Animals (8th Ed., NRC 2011) for animal husbandry. All experimental procedures were approved by the Texas Tech University IACUC. Casp1/11−/− mice on the C57BL/6 background (stock: 016621) and wild type C57BL/6 mice (stock: 000664) were purchased from The Jackson Laboratory (Bar Harbor, ME). Mice of both genders aged 6–15 weeks were used to prepare BMDM. Sample size was determined as the minimum number of mice needed to provide sufficient bone marrow for experiments. Consequently, no randomization or impairment was needed. Euthanasia was performed by asphyxiation through controlled flow of pure CO2 gas. Mice of both genders aged 6–15 weeks were used to prepare BMDM. Sample size was determined as the minimum number of mice needed to provide sufficient bone marrow for experiments. Consequently, no randomization or impairment was needed. Euthanasia was performed by asphyxiation through controlled flow of pure CO2 gas followed by cervical dislocation.

Cell Culture. Bone-marrow derived macrophages (BMDM) were isolated from femora and tibiae and cultured as previously described. Briefly, BMDM were differentiated at 37°C, 5% CO2 for 7–21 days in DMEM supplemented with 30% L929 cell supernatant, 20% FCS (VWR Seradigm, Radnor, PA), 1 mM sodium pyruvate (Corning, Corning, NY), 1x Penicillin/Streptomycin (Hyclone, Logan, UT), and 1x L-glutamine (HyClone).

TNFα induction and FACS staining of cells. BMDM were unchallenged (control) or challenged with a sublytic dose of SLO WT, PFO, SLO N402C, or a mass of SLO ML or SLO N402E equivalent to the highest SLO WT or SLO N402C dose for 10 min at 37°C in RPMI media supplemented with 2 mM CaCl2. Toxin was neutralized by addition of 10% FCS, followed by dilution with RPMI and centrifugation at 500 × g for 10 min. Cells were
then resuspended in RPMI supplemented with 10% FCS, 1x Penicillin/Streptomycin and 1x L-glutamine (R10) and stimulated with 100 endotoxin units (EU)/mL LPS, 10 μg/mL poly I:C, 1 μg/mL Pam3CSK4, or 75 ng/mL IFN-γ, for 2 h unless otherwise mentioned. Brefeldin A (BFA) was added at 5 μg/mL 30 min after stimulation. Cells were then fixed in 2% paraformaldehyde for 15 min on ice, permeabilized using 0.1% saponin in FACS buffer for 10 min on ice, washed and stained with 5 μg/mL anti-TNFα conjugated to FITC for 40 min on ice, washed and analyzed in FACS buffer on an Accuri C6 (BD Biosciences, San Jose, CA). The percentage of TNFα positive cells was determined after gating on live cells, while the percentage of dead cells was determined either by the Ghost Red high population or PI staining of a subsample. For other surface marker staining, cells were challenged with CDCs and stimulated with LPS or other agonists as described above. However, cells were stimulated without BFA, incubated overnight instead of 2 h, neither fixed nor permeabilized but instead surface stained for 30 min on ice with anti-CD69 FITC, anti-CD80 PE and anti-CD86 APC conjugated antibodies. The mean fluorescence intensity (MFI) of the respective surface marker was determined from live cells and percentage of dead cells was determined by the percentage Ghost Red bright cells using a FACS Aria III (BD Biosciences, San Jose, CA).

**Cell Sorting.** BMDM were unchallenged or challenged with 500 HU/mL SLO WT for 10 min at 37 °C in RPMI supplemented with 2 mM CaCl2. Toxin was neutralized by addition of 10% FCS followed by dilution in RPMI. Cells were centrifuged at 500 × g for 10 min, resuspended in PBS containing 2% FCS and 20 μg/mL PI and the PI negative population was sorted on a FACS Aria III (BD Biosciences). Sorted cells were resuspended in R10 and stimulated with 100 EU/mL LPS for 2 h followed by intracellular cytokine staining with APC-conjugated anti-TNFα as described above.

**Apoptosis Assay.** BMDM were unchallenged or challenged with SLO WT, PFO or a mass equivalent of SLO ML for 10 min at 37 °C in the presence of FM1–43X, then washed with PBS to remove excess toxin and dye, resuspended in R10, stimulated with 100 EU/mL LPS for 2 h and stained using APC anti-TNFα as described above. The percentage of TNFα positive cells were determined from both FM1–43Xm (high repair) and FM1–43Xl (low repair) populations. Alternatively, BMDM were challenged with CDCs in the absence of FM1–43FX for 10 min at 37 °C, resuspended and stimulated with 100 EU/mL LPS as described above. Cells were harvested, stained with Ghost Red, then FITC anti-LAMP1, followed by fixation, permeabilization and staining as described above for intracellular TNFα cytokine staining. The percentage of TNFα positive cells were determined from live cells with either low or high LAMP1 staining.

**Isolation of Microvesicles.** Microvesicles were isolated as described previously 54. Briefly, 5 × 10^6–1 × 10^7 cells were harvested, resuspended in RPMI media supplemented with 2 mM CaCl2, to 2.5 × 10^6–5 × 10^6 cells/mL, challenged with a sublytic concentration of toxin (hemolytic toxins) or equivalent mass (inactive toxins) and incubated for 15 min at 37 °C. Cells were pelleted at 2,000 × g for 5 min, solubilized at 95 °C in SDS-sample buffer for 5 min and sonicated. Supernatants were spun at 100,000 × g in a Beckman Coulter TL-100 ultracentrifuge using a Beckman TLS 55 rotor for 40 min at 4 °C. Both high-speed supernatant and microvesicle pellet were solubilized at 95 °C in 4 × SDS-sample buffer for 5 min.

**SDS-PAGE and Immunoblotting.** The low speed cell pellet, high speed supernatant, and microvesicle samples from BMDM challenged with CDCs as described above were resolved on 10% polyacrylamide gels at 90 V for 165 min and transferred in an ice bath to nitrocellulose in transfer buffer (15.6 mM Tris and 150 mM NaCl and 0.1% Tween 20 (TBST), incubated with 6D11 anti-SLO mAb (1:1000), 4B4F12 anti-CD14 mAb (1:1000), 76B357.1 anti-TLR4 rAb (1:500), O91B8 anti-MyD88 mAb (1:1000), MANLAC-4A7 anti-Lamin A/C mAb (1:250), AC-15 anti-β-Actin mAb (1:5000), 1H4B01 anti-TrIF rAb (1:1000), EPR4477 anti-Alkaline Phosphatase rAb (1:1000) or anti-IFN-γ1 goat polyclonal antibody (1:1000) in 1% skim milk in TBST followed by HRP-conjugated anti-mouse, anti-rabbit or anti-goat IgG antibodies in 1% skim milk in TBST and developed with ECL (0.01% H2O2 (Walmart, Fayetteville, AR), 0.2 mM p-Coumaric acid (Sigma), 1.25 mM Luminal (Sigma), 0.1M Tris pH 8.4).

**Lipid Assays.** Microvesicles were isolated as described above from BMDM challenged with SLO or PFO. Lipids were extracted from the microvesicle pellets using 200 μL methanol for 30 min at room temperature and centrifuged at 12,000 × g for 2 min at room temperature. Supernatants were assayed for total cholesterol content (Catalog: 10007640, Cayman Chemicals, Ann Arbor, MI) and phospholipid content (Catalog: EPLP-100, BioAssay Systems, Hayward, CA) according to manufacturer’s instructions. Fluorescence was read using 535 excitation and 585 emission filters on a FL600 fluorescence microplate reader (Biotek, Winooski, VT).

**RT-PCR.** Cells were treated with toxins as described above followed by 2 or 4 h of stimulation with 100 EU/mL LPS at 37 °C. Total RNA was extracted using TRI-Reagent. cDNA was generated using Superscript III. TNFα and β-actin levels were measured on an ABI 7300 using SybrGreen and compared using ΔΔCt as previously described 76. Primer sequences for β-actin are 5′-GAAATCTGCGGCGATCAGGAGG and 5′-TGATGTTTCATGTGACGCG and for TNFα are 5′-CCTGATGCCCACGTCTGAG and 5′-GGGAGTACCAAGGTTCAACCC.
Statistics. Origin software (Northampton, MA) was used for statistical analysis. Data are represented as mean ± SEM. Statistical significance was determined by Two-way ANOVA with Bonferroni post-testing. p < 0.05 was considered statistically significant. Graphs were generated in Excel (Microsoft, Redmond, WA) and Photoshop (Adobe Systems Incorporated, San Jose, CA).

Data availability. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request. Full western blots used to construct Fig. 5 are available as Supplementary Data (Supplementary Figs S1–S2).

References
1. Misiakos, E. P. et al. Current concepts in the management of necrotizing fasciitis. Frontiers in surgery 1, 36, https://doi.org/10.3389/fsurg.2014.00036 (2014).
2. Hakkarainen, T. W., Kopari, N. M., Pham, T. N. & Evans, H. L. Necrotizing soft tissue infections: review and current concepts in treatment, systems of care, and outcomes. Current problems in surgery 51, 344–362, https://doi.org/10.1007/s10663-014-0601-1 (2014).
3. Donaldson, P. M., Naylor, B., Lowe, J. W. & Gouldesbrough, D. R. Rapidly fatal necrotising fasciitis caused by Streptococcus pyogenes. J Clin Pathol 46, 617–620 (1993).
4. Bryant, A. E. et al. Clostridium perfringens invasiveness is enhanced by effects of theta toxin upon PMNL structure and function: the roles of leukocytotoxicity and expression of CD11/CD18 adherence glycoprotein. FEMS Immunol Med Microbiol 7, 321–336 (1993).
5. Awad, M. M., Ellemor, D. L., Boyd, R. L., Emmins, J. J. & Rood, J. I. Synergistic effects of alpha-toxin and perfringolysin O in Clostridium perfringens-mediated gas gangrene. Infect Immun 69, 7904–7910, https://doi.org/10.1128/IAI.69.12.7904-7910.2001 (2001).
6. Stevens, D. L., Tweten, R. K., Awad, M. M., Rood, J. I. & Bryant, A. E. Clostridial gas gangrene: evidence that alpha and theta toxins are required for vascular leukostasis to occur in experimental gas gangrene. Infect Immun 67, 4902–4907 (1999).
7. Stevens, D. L. & Bryant, A. E. The role of clostridial toxins in the pathogenesis of gas gangrene. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 35, S93–S100, https://doi.org/10.1086/519928 (2002).
8. Romero, M. et al. Clostridium perfringens-mediated gas gangrene. FEMS Immunol Med Microbiol 52, 638–6430 (2009).
9. Bricker, A. L., Cywes, C., Ashbaugh, C. D. & Wessels, M. R. NAD+-glycohydrolase acts as an intracellular toxin to enhance the extracellular survival of group A streptococci. Mol Microbiol 44, 257–269 (2002).
10. Hanz, D. et al. Inhibition of Inflammasome-Dependent Interleukin Ibeta Production by Streptococcal NAD+-Glycohydrolase: Evidence for Extracellular Activity. mBio 8, https://doi.org/10.1128/mBio.00756-17 (2017).
11. Velarde, J. J., O’Seaghdha, M., Baddal, B., Bastiat-Sempe, B. & Wessels, M. R. Binding of NAD+-Glycohydrolase to Streptolysin O Stabilizes Both Toxins and Promotes Virulence of Group A Streptococci. mBio 8, https://doi.org/10.1128/mBio.01382-17 (2017).
12. Magassa, N., Chandrasekaran, S. & Caparon, M. G. Streptococcus pyogenes cytolysin-mediated translocation does not require pore formation. Biochemistry 38, 15204–15211 (1999).
13. Awad, M. M., Tweten, R. K., Awad, M. M., Rood, J. I. & Bryant, A. E. Clostridial gas gangrene: evidence that alpha and theta toxins are required for vascular leukostasis to occur in experimental gas gangrene. Infect Immun 67, 4902–4907 (1999).
14. Romero, M. et al. Clostridium perfringens-mediated gas gangrene. FEMS Immunol Med Microbiol 52, 638–6430 (2009).
15. Keyel, P. A., Roth, R., Yokoyama, W. M., Heuser, J. E. & Salter, R. D. Reduction of streptolysin O (SLO) pore-forming activity diminishes inflammasome activation. Toxins (Basel) 5, 1105–1118, https://doi.org/10.3390/toxins5061105 (2013).
16. Romero, M. et al. Intrinsic repair protects cells from pore-forming toxins by microvesicle shedding. Cell Death Differ 24, 798–808, https://doi.org/10.1038/cdd.2017.11 (2017).
17. Magassa, N., Chandrasekaran, S. & Caparon, M. G. Streptococcus pyogenes cytolysin-mediated translocation does not require pore formation by streptolysin O. EMBO Rep 11, 400-405, doi:10.15252/embr.2010337 (2010).
18. Abdel Ghani, E. M. et al. Streptolysin O: inhibition of the conformational change during membrane binding of the monomer prevents oligomerization and pore formation. Biochemistry 38, 15204–15211 (1999).
19. Hotze, E. M. et al. Arresting pore formation of a cholesterol-dependent cytolysin by disulfide trapping synchronizes the insertion of the transmembrane beta-sheet from a prepore intermediate. J Biol Chem 276, 8261–8268, https://doi.org/10.1074/jbc.M009865200 (2001).
20. Ramachandran, R., Tweten, R. K. & Johnson, A. E. Membrane-dependent conformational changes initiate cholesterol-dependent cytolysin oligomerization and internus beta-strand alignment. Nat Struct Mol Biol 11, 697–705, https://doi.org/10.1038/nsmb793 (2004).
21. Goldmann, O., Sastalla, I., Wos-Oxley, M., Rohde, M. & Medina, E. Streptococcus pyogenes induces oncoisosis in macrophages through the activation of an inflammatory programmed cell death pathway. Cell Microbiol 11, 138–155 (2009).
22. Timmer, M. A. et al. Streptolysin O promotes group A Streptococcus immune evasion by accelerated macrophage apoptosis. J Biol Chem 284, 862–871 (2009).
23. O’Brien, D. K. & Melville, S. B. Effects of Clostridium perfringens alpha-toxin (PLC) and perfringolysin O (PFO) on cytotoxicity to macrophages, on escape from the phagosomes of macrophages, and on persistence of C. perfringens in host tissues. Infect Immun 72, 5204–5215, https://doi.org/10.1128/IAI.72.9.5204-5215.2004 (2004).
24. Cywes Bentley, C., Hakansson, A., Christianson, J. & Wessels, M. R. Extracellular group A Streptococcus induces keratinocyte apoptosis by dysregulating calcium signalling. Cell Microbiol 7, 945–955, https://doi.org/10.1046/j.1462-5825.2005.00525.x (2005).
25. Love, J. F., Tran-Winkler, H. J. & Wessels, M. R. Vitamin D and the human antimicrobial peptide LL-37 enhance group A Streptococcus survival in macrophages. mBio 5, e01690–01614, https://doi.org/10.1128/mBio.01690-14 (2014).
26. Portnoy, D. A., Jacks, P. S. & Hinrichs, D. J. Role of hemolysin for the intracellular growth of Listeria monocytogenes. J Exp Med 167, 1459–1471 (1988).
27. Portnoy, D. A., Awad, M. M., Kehoe, M. B. & Bielecki, J. Capacity of listeriolysin O, streptolysin O, and perfringolysin O to mediate growth of Bacillus subtilis within mammalian cells. Infect Immun 66, 2710–2717 (1998).
28. Uchiyama, S. et al. Streptolysin O Rapidly Impairs Neutrophil Oxidative Burst and Antibacterial Responses to Group A Streptococcus. Front Immunol 6, 581, https://doi.org/10.3389/fimmu.2015.00581 (2015).
29. Saenz, A. J., Koreishi, A. F., Rosenberg, A. E. & Kradin, R. L. Immune cell subsets in necrotizing fasciitis: an immunohistochemical analysis. Virchows Archiv: an international journal of pathology 455, 87–92, https://doi.org/10.1007/s00428-009-0781-3 (2009).
57. McNeil, A. K., Rescher, U., Gerke, V. & McNeil, P. L. Requirement for annexin A1 in plasma membrane repair.

58. Reddy, A., Caler, E. V. & Andrews, N. W. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. PLoS Pathog 7, e1002229, https://doi.org/10.1371/journal.ppat.1002229 (2011).

59. Keyel, A., Chakrabarti, C. P. & Roy, S. Interplay of cholesterol and TLR5 in immune responses. J Immunol 184, 499–505 (2010).

60. McNeill, P. L. Membrane Repair: Mechanisms and Pathophysiology. Physiol Rev 95, 1205–1240, https://doi.org/10.1152/physrev.00073.2014 (2015).

61. McNeill, P. L. Cholesterol function in plasma membranes from ectotherms: Membrane-specific roles in adaptation to temperature. J Exp Biol 216, 2113–2118 (1986).

62. Sprigs, D. R. et al. Phospholipase A2 activation and autoinduction of tumor necrosis factor gene expression by tumor necrosis factor. Cancer Res 50, 7101–7107 (1990).

63. Crockett, E. L. Cholesterol function in plasma membranes from ectotherms: Membrane-specific roles in adaptation to temperature. J Exp Biol 216, 2113–2118 (1986).

64. Garry, R. F., Bostick, D. A., Schram, R. & Waite, M. R. The ratio of plasma membrane cholesterol to phospholipid and the inhibition of Sindbis virus maturation by low NaCl medium. The Journal of general virology 66(Pt 5), 1171–1177, https://doi.org/10.1099/0022-1317-66-5-1171 (1985).

65. Nelson, L. D., Chiantia, S. & London, E. Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gammaR subunit assembly, IFN-gamma signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterol. Cytokine 50, 7101–7107 (1990).

66. McNeill, P. L. Lipid microdomains are required sites for the selective endocytosis and nuclear translocation of IFN-gamma, its receptor chain IFN-gamma receptor-1, and the phosphorylation and nuclear translocation of STAT1 alpha. J Immunol 169, 1959–1969 (2002).

67. Nelson, L. D., Chiantia, S. & London, E. Perfringolysin O association with ordered lipid domains: implications for transmembrane protein raft affinity. Biophys J 99, 3255–3263, https://doi.org/10.1016/j.bpj.2010.09.028 (2010).

68. Xie, M. & Low, M. G. Streptolysin-O induces release of glycosylphosphatidylinositol-anchored alkaline phosphatase from ROS cells by vesiculation independently of phospholipase action. Biochem J 305( Pt 2), 529–537 (1995).

69. Wale, I., Vollmer, P., Palmer, M., Bhakdi, S. & Rose-John, S. Pore-forming toxins trigger shedding of receptors for interleukin-6 and lipopolysaccharide. Proc Natl Acad Sci USA 93, 7882–7887 (1996).

70. Keyel, P. A. et al. Streptolysin O clearance through sequestration into blebs that bud passively from the plasma membrane. J Cell Biol 124, 2414–2423, doi:10.1083/jcb.076182 (2011).

71. Butte, M. J., Keir, M. E., Phamduv, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the CD80/CD86 receptor complex and is upregulated in cytotoxic T lymphocytes. Proc Natl Acad Sci USA 93, 660–665, https://doi.org/10.1073/pnas.93.2.660 (1996).

72. Sansom, D. M., Manzotti, C. N. & Zheng, Y. What’s the difference between CD80 and CD86? Trends Immunol 24, 314–319 (2003).

73. McNiel, A. K., Rescher, U., Gerke, V. & McNeil, P. L. Requirement for annexin A1 in plasma membrane repair. J Biol Chem 281, 3522–35207 (2006).

74. Reddy, A., Caler, E. V. & Andrews, N. W. Plasma membrane repair is mediated by Ca(2+)-regulated exocytosis of lysosomes. Cell 106, 157–169 (2001).

75. McNeill, P. L., Miyake, K. & Vogel, S. S. The endomembrane requirement for cell surface repair. Proc Natl Acad Sci USA 100, 4592–4597 (2003).

76. Eder, A. & Augustin, C. C. Intracellular trafficking of NLRP3 inflammasome by Streptococcus pyogenes requires streptolysin O and NF-kappa B activation but proceeds independently of TLR signaling and P2X7 receptor. Journal of immunology 183, 5823–5829, https://doi.org/10.4049/jimmunol.0900444 (2009).

77. Miao, E. A., Rajan, J. V. & Aderem, A. Caspase-1-induced pyroptotic cell death. Immunity 23, 205–215, https://doi.org/10.1016/j.immuni.2005.05.007 (2005).

78. O’Neill, L. A., Golenbock, D. & Bowie, A. G. The history of Toll-like receptors - redefining innate immunity. Nat Rev Immunol 13, 453–460, https://doi.org/10.1038/nri3446 (2013).

79. Keyel, P. A., Tkacheva, O. A., Larregina, A. T. & Sailer, R. D. Coordinate stimulation of macrophages by microparticles and TLR ligands induces foam cell formation. J Immunol 189, 4621–4629, doi:10.1162/jimmunol.1200828 (2012).

80. Hoebe, K. et al. Upregulation of costimulatory molecules induced by lipopolysaccharide and double-stranded RNA occurs through a T cell-dependent and T cell-independent pathways. Nat Immunol 4, 1223–1229, https://doi.org/10.1038/nri1010 (2003).

81. Keyel, P. A. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. Cytokine 69, 136–145, https://doi.org/10.1016/j.cyto.2014.03.007 (2014).

82. De Nardo, D., De Nardo, C. M. & Latz, E. New insights into mechanisms controlling the NLRP3 inflammasome and its role in lung disease. Am J Pathol 184, 42–54, https://doi.org/10.1016/j.ajpath.2013.09.007 (2014).

83. Zhu, X. & Berliner, J. A. Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. Journal of lipid research 51, 3196–3206, https://doi.org/10.1194/jlr.M0060486 (2010).

84. Miller, H. et al. Lipid raft-dependent plasma membrane repair interferes with the activation of B lymphocytes. J Cell Biol 211, 1193–1205, https://doi.org/10.1083/jcb.201505030 (2015).
69. Gong, Y. N. et al. ESCRT-III Acts Downstream of MLKL to Regulate Necroptotic Cell Death and Its Consequences. Cell 169, 286–300 e216, https://doi.org/10.1016/j.cell.2017.03.020 (2017).

70. Park, J. M., Ng, V. H., Maeda, S., Rest, R. F. & Karin, M. Anthrolysin O and other gram-positive cytolsins are toll-like receptor 4 agonists. J Exp Med 200, 1647–1655 (2004).

71. Malley, R. et al. Recognition of pneumolysin by Toll-like receptor 4 confers resistance to pneumococcal infection. Proc Natl Acad Sci USA 100, 1966–1971, https://doi.org/10.1073/pnas.0435928100 (2003).

72. Srivastava, A. et al. The apoptotic response to pneumolysin is Toll-like receptor 4 dependent and protects against pneumococcal disease. Infect Immun 73, 6479–6487, https://doi.org/10.1128/IAI.73.10.6479-6487.2005.

73. Shepard, L. A. et al. Identification of a membrane-spanning domain of the thiol-activated pore-forming toxin Clostridium perfringens perfringolysin O: an alpha-helical to beta-sheet transition identified by fluorescence spectroscopy. Biochemistry 37, 14563–14574 (1998).

74. Keyel, P. A., Heid, M. E., Watkins, S. C. & Salter, R. D. Visualization of bacterial toxin induced responses using live cell fluorescence microscopy. J Vis Exp e4227, doi:4227 (2012).

75. Heid, M. E. et al. Mitochondrial Reactive Oxygen Species Induces NLRP3-Dependent Lysosomal Damage and Inflammasome Activation. Journal of immunology 191, 5230–5238, https://doi.org/10.4049/jimmunol.1301490 (2013).

76. Keyel, P. A. et al. Methylthioadenosine reprograms macrophage activation through adenosine receptor stimulation. PLoS One 9, e104210, https://doi.org/10.1371/journal.pone.0104210 (2014).

Acknowledgements
We would like to thank Kai Zhang for use of his flow cytometer, Mary Catherine Hastert for technical assistance with cell sorting, the College of Arts & Sciences Microscopy, Texas Tech University (Lubbock, TX) for use of their facilities and members of the Keyel lab for critical reading of the manuscript. This work was supported by Texas Tech University start-up funds and American Heart Association Scientist Development Grant (16SDG302000016) to PAK.

Author Contributions
P.B. designed and performed experiments, analyzed the data, and prepared the manuscript; P.A.K. conceived the idea, designed experiments, analyzed the data, provided resources and prepared the manuscript.

Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-24955-2.

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018